Melissa M. Budelier
Melissa M. Budelier has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Alex S. Evers
Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO 63110, USA
4 shared publications Kathiresan Krishnan
Anesthesiology, Washington University in St. Louis, Saint Louis, MO, USA
3 shared publications- Alejandro R. Molinelli
Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital , Memphis, TN
2 shared publications Douglas F. Covey
From the Departments of Anesthesiology
2 shared publications- Gustav Akk
Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri; Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine, St. Louis, Missouri
2 shared publications - James W. Janetka
Department of Biochemistry and Molecular Biophysics Washington University School of Medicine St. Louis MO 63110 USA
2 shared publications
Latest Publications
- 27 May 2026
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 72 (11) , 1107-1109
Blood Phosphorylated Tau for the Diagnosis of Alzheimer Disease
- 27 May 2026
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 72 (11) , 1107-1109
Blood Phosphorylated Tau for the Diagnosis of Alzheimer Disease
- Open Access
- 5 May 2026
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 11 (3) , 673-676
Ethics through the Years: The Evolution of Ethical Guidelines for ADLM
- 5 May 2026
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 11 (3) , 673-676
Open AccessEthics through the Years: The Evolution of Ethical Guidelines for ADLM
- Open Access
- 7 January 2026
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 11 (3) , 531-541
Tacrolimus Assay Comparison: Analytical and Operational Considerations for Immunoassay vs Mass Spectrometry Testing in a High Volume Clinical Laboratory
Background: Tacrolimus therapeutic drug monitoring is a routine and critical assay for managing transplant patients. Tacrolimus can be measured from whole blood samples via liquid chromatography–tandem mass spectrometry (LC-MS/MS) or immunoassay (IA). LC-MS/MS provides accurate parent drug quantification with minimal metabolite interference but requires expensive analyzers, highly trained staff, and is often a very manual process. Immunoassays offer faster, simpler workflows, but historically have been prone to significant cross-reaction with the drug’s metabolites or other therapeutic drugs, leading to a falsely elevated result. Newer immunoassays show promising improvements in specificity. Methods: Using 73 residual patient samples, we compared our in-house LC-MS/MS tacrolimus assay to the Roche Elecsys® tacrolimus electrochemiluminescence immunoassay on the cobas® e801 analyzer. Comparative analysis was done with Deming regression and Bland–Altman comparison. Linearity, within-individual imprecision, and total imprecision post immunoassay implementation were also evaluated, along with changes and improvements to workflow and turnaround times (TAT). Results: The Roche Elecsys tacrolimus assay correlated well with our LC-MS/MS method (Deming regression equation: y = 1.004x + 0.4848). The bias was 0.52 ng/mL (an average of 8.1%) as determined by Bland–Altman comparison. When switching to the immunoassay we observed a 42%–51% improvement in TAT across the median, 75th percentile, and 90th percentile. Conclusions: We observed excellent correlation between the Roche Elecsys tacrolimus assay on an e801 analyzer vs our in-house LC-MS/MS assay, with good precision and linearity across reportable ranges. Changing from mass spectrometry to tacrolimus immunoassay substantially improved our TAT and workflow.
- 7 January 2026
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 11 (3) , 531-541
Open AccessTacrolimus Assay Comparison: Analytical and Operational Considerations for Immunoassay vs Mass Spectrometry Testing in a High Volume Clinical Laboratory
Background: Tacrolimus therapeutic drug monitoring is a routine and critical assay for managing transplant patients. Tacrolimus can be measured from whole blood samples via liquid chromatography–tandem mass spectrometry (LC-MS/MS) or immunoassay (IA). LC-MS/MS provides accurate parent drug quantification with minimal metabolite interference but requires expensive analyzers, highly trained staff, and is often a very manual process. Immunoassays offer faster, simpler workflows, but historically have been prone to significant cross-reaction with the drug’s metabolites or other therapeutic drugs, leading to a falsely elevated result. Newer immunoassays show promising improvements in specificity. Methods: Using 73 residual patient samples, we compared our in-house LC-MS/MS tacrolimus assay to the Roche Elecsys® tacrolimus electrochemiluminescence immunoassay on the cobas® e801 analyzer. Comparative analysis was done with Deming regression and Bland–Altman comparison. Linearity, within-individual imprecision, and total imprecision post immunoassay implementation were also evaluated, along with changes and improvements to workflow and turnaround times (TAT). Results: The Roche Elecsys tacrolimus assay correlated well with our LC-MS/MS method (Deming regression equation: y = 1.004x + 0.4848). The bias was 0.52 ng/mL (an average of 8.1%) as determined by Bland–Altman comparison. When switching to the immunoassay we observed a 42%–51% improvement in TAT across the median, 75th percentile, and 90th percentile. Conclusions: We observed excellent correlation between the Roche Elecsys tacrolimus assay on an e801 analyzer vs our in-house LC-MS/MS assay, with good precision and linearity across reportable ranges. Changing from mass spectrometry to tacrolimus immunoassay substantially improved our TAT and workflow.
- Open Access
- 1 January 2026
- Published by Stanford University Press in Journal of Mass Spectrometry and Advances in the Clinical Lab
- Vol. 39 (1)
LDT’s in Flux: Will Evolving Regulations Enhance or Complicate Laboratory Practices?
Clinical labs help diagnose and manage disease by testing blood and other specimens. They operate under federal rules known as Clinical Laboratory Improvement Amendments (CLIA). Most tests are FDA cleared/approved, but some are laboratory-developed tests (LDTs) created in individual labs, typically to meet unmet needs. LDTs have long existed in a complicated regulatory space. In 2024, the FDA issued a rule to regulate LDTs like devices, prompting concerns about cost, innovation, and access. A federal court struck the rule down in 2025, finding LDTs are services, not devices. The FDA subsequently rescinded its rule. In this article, experts argue that LDTs are essential and already held to strong standards and that future reforms should strengthen CLIA while protecting access and innovation.
- 1 January 2026
- Published by Stanford University Press in Journal of Mass Spectrometry and Advances in the Clinical Lab
- Vol. 39 (1)
Open AccessLDT’s in Flux: Will Evolving Regulations Enhance or Complicate Laboratory Practices?
Clinical labs help diagnose and manage disease by testing blood and other specimens. They operate under federal rules known as Clinical Laboratory Improvement Amendments (CLIA). Most tests are FDA cleared/approved, but some are laboratory-developed tests (LDTs) created in individual labs, typically to meet unmet needs. LDTs have long existed in a complicated regulatory space. In 2024, the FDA issued a rule to regulate LDTs like devices, prompting concerns about cost, innovation, and access. A federal court struck the rule down in 2025, finding LDTs are services, not devices. The FDA subsequently rescinded its rule. In this article, experts argue that LDTs are essential and already held to strong standards and that future reforms should strengthen CLIA while protecting access and innovation.
- 30 December 2025
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 72 (1) , 39-46
From Diagnostics to Data Analytics: A Strategic Approach to Closing Care Gaps in Pregnancy
Background: Persistent disparities in prenatal care contribute to preventable maternal and fetal morbidity and mortality, particularly among high-risk and underserved populations. Clinical laboratories play a central role in early detection of prenatal gaps in care and stratifying pregnancy-related risk factors linked to other health conditions, yet their full potential remains underutilized. Content: This review examines the integration of data analytics with laboratory information systems and electronic health records to proactively identify and address lapses in prenatal care. Structured laboratory data can drive clinical decision support, stratify risk in early pregnancy, and guide targeted interventions. Predictive analytics and population health tools are discussed as mechanisms to uncover disparities in access, optimize resource allocation, and inform system-level strategies. While there are critical challenges that must be addressed, including data interoperability, incomplete data sets, and ethical considerations such as patient autonomy and data privacy, data analytics can be leveraged to advance prenatal care. Summary: By centering diagnostic data within the broader analytics framework, clinical laboratories are positioned to lead multidisciplinary efforts to deliver more equitable and effective maternal healthcare.
- 30 December 2025
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 72 (1) , 39-46
From Diagnostics to Data Analytics: A Strategic Approach to Closing Care Gaps in Pregnancy
Background: Persistent disparities in prenatal care contribute to preventable maternal and fetal morbidity and mortality, particularly among high-risk and underserved populations. Clinical laboratories play a central role in early detection of prenatal gaps in care and stratifying pregnancy-related risk factors linked to other health conditions, yet their full potential remains underutilized. Content: This review examines the integration of data analytics with laboratory information systems and electronic health records to proactively identify and address lapses in prenatal care. Structured laboratory data can drive clinical decision support, stratify risk in early pregnancy, and guide targeted interventions. Predictive analytics and population health tools are discussed as mechanisms to uncover disparities in access, optimize resource allocation, and inform system-level strategies. While there are critical challenges that must be addressed, including data interoperability, incomplete data sets, and ethical considerations such as patient autonomy and data privacy, data analytics can be leveraged to advance prenatal care. Summary: By centering diagnostic data within the broader analytics framework, clinical laboratories are positioned to lead multidisciplinary efforts to deliver more equitable and effective maternal healthcare.
- Open Access
- 1 December 2025
- Published by Stanford University Press in Journal of Mass Spectrometry and Advances in the Clinical Lab
LDT’s in flux: will evolving regulations enhance or complicate laboratory practices?
- 1 December 2025
- Published by Stanford University Press in Journal of Mass Spectrometry and Advances in the Clinical Lab
Open AccessLDT’s in flux: will evolving regulations enhance or complicate laboratory practices?
- Open Access
- 6 March 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (5) , 3661-3663
Blood tests for Alzheimer's disease: The impact of disease prevalence on test performance
- 6 March 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (5) , 3661-3663
Open AccessBlood tests for Alzheimer's disease: The impact of disease prevalence on test performance
- Open Access
- 1 August 2023
- Published by Stanford University Press in Journal of Mass Spectrometry and Advances in the Clinical Lab
- Vol. 29, 1
An introduction from the Laboratory Developed Tests special issue guest editors
- 1 August 2023
- Published by Stanford University Press in Journal of Mass Spectrometry and Advances in the Clinical Lab
- Vol. 29, 1
Open AccessAn introduction from the Laboratory Developed Tests special issue guest editors
- Open Access
- 1 April 2023
- Published by Stanford University Press in Journal of Mass Spectrometry and Advances in the Clinical Lab
- Vol. 28, 67-69
The regulatory landscape of laboratory developed tests: Past, present, and a perspective on the future
- 1 April 2023
- Published by Stanford University Press in Journal of Mass Spectrometry and Advances in the Clinical Lab
- Vol. 28, 67-69
Open AccessThe regulatory landscape of laboratory developed tests: Past, present, and a perspective on the future
- Open Access
- 1 March 2023
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 69 (3) , 225-226
Commentary on Unexpected Fentanyl Detection during a Liver Transplant Evaluation
This case highlights the potential consequences that false-positive (FP) urine drug screen (UDS) results can have on patient care and reinforces the need to confirm preliminary screen results with a direct method, such as liquid chromatography–tandem mass spectrometry (LC-MS/MS). Rather than act on the unexpected results, the transplant team appropriately consulted the laboratory and confirmatory testing was performed. Neither fentanyl or norfentanyl were detected on the LC-MS/MS confirmation assay, meaning the immunoassay screen result was a FP.
- 1 March 2023
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 69 (3) , 225-226
Open AccessCommentary on Unexpected Fentanyl Detection during a Liver Transplant Evaluation
This case highlights the potential consequences that false-positive (FP) urine drug screen (UDS) results can have on patient care and reinforces the need to confirm preliminary screen results with a direct method, such as liquid chromatography–tandem mass spectrometry (LC-MS/MS). Rather than act on the unexpected results, the transplant team appropriately consulted the laboratory and confirmatory testing was performed. Neither fentanyl or norfentanyl were detected on the LC-MS/MS confirmation assay, meaning the immunoassay screen result was a FP.